MetaCap

Gain Therapeutics (GANX) vs Milestone Pharmaceuticals (MIST)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Gain Therapeutics (GANX) has outperformed Milestone Pharmaceuticals (MIST) over the past year, losing 62.4% versus a loss of 84.5%. Over five years, GANX leads with a -87.3% price change compared with -93.8% for MIST. Milestone Pharmaceuticals is the larger company by market cap ($46.2 million vs $44.5 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

GANX-62.43%MIST-84.54%
+64%-14%-92%
Nov 21, 20251 yearNov 20, 2026
GANX-87.92%MIST-93.88%
+64%-19%-101%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

GANX versus MIST key metrics
MetricGANXMIST
Share price$0.9994$0.3711
Market cap$44.50M$46.20M
1-day change-4.82%-7.06%
YTD return-68.96%-81.63%
1-year return-62.43%-84.54%
5-year return-87.27%-93.85%
EPS (TTM)$-0.42$-0.74
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-20.16M$-63.06M
52-week high$4.34$3.06
52-week low$0.94$0.362
Distance from 52-week high-76.97%-87.87%
Analyst consensusstrong_buynone
Avg. price target upside+620.43%+1479.09%
Average volume550.22K1.53M
Shares outstanding44.53M124.50M
Employees2038
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • GANX has outperformed MIST by 22.1 percentage points over the past year.

About Gain Therapeutics

GANX stock →

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company's drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 20 employees

About Milestone Pharmaceuticals

MIST stock →

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults.

Health Care · Biotechnology: Pharmaceutical Preparations · 38 employees

GANX vs MIST FAQ

Which is bigger, Gain Therapeutics or Milestone Pharmaceuticals?

Milestone Pharmaceuticals (MIST) is larger, with a market capitalization of $46.20M compared with $44.50M for Gain Therapeutics (GANX).

Which stock has performed better over the past year, GANX or MIST?

GANX returned -62.43% over the past 12 months, compared with -84.54% for MIST (price return, excluding dividends). Past performance does not predict future results.

Are Gain Therapeutics and Milestone Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons